AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 21051252
Drug: Insulin infusion
RxNorm normalized name: iLet Insulin Infusion 10-Pack Kit Inset
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin infusion (1.6 mU/kg/h) for 4 hours before hemodialysis
Trial: 15563637
Drug: Arbitrary‐pressure CPAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arbitrary‐pressure CPAP based on body mass index before treatment polysomnography
Trial: 12125474
Drug: Calcimax (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcimax (200 mg per capsule, 2 capsules after light supper for 6 months)
Trial: 10427881
Drug: Tramadol 1
RxNorm normalized name: tramadol 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol 1 mg/kg s.c.
Trial: 7579506
Drug: No adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No adjuvant hormone therapy
Trial: 2223432
Drug: Nimodipine (calcium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimodipine (calcium antagonist)
Trial: 22228638
Drug: Sorafenib 200
RxNorm normalized name: sorafenib 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorafenib 200 mg twice daily plus temsirolimus 25 mg weekly (Arm A)
Trial: 22228638
Drug: Sorafenib 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorafenib 400 mg every morning, 200 mg every night plus tipifarnib 100 mg twice daily (Arm B)
Trial: 17928091
Drug: Group A:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A: rapid tapering and withdrawal 91 days after LT
Trial: 17928091
Drug: Group B:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B: slow tapering and withdrawal 25 months after LT
Trial: 9579769
Drug: Trandolapril (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trandolapril (0.25 to 16 mg/day)
Trial: 7666079
Drug: Suramin and
RxNorm normalized name: suramin
DrugBank: Suramin (DB04786)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suramin and hydrocortisone (cohort A: loading dose followed by continuous infusion)
Trial: 7666079
Drug: Suramin and
RxNorm normalized name: suramin
DrugBank: Suramin (DB04786)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suramin and hydrocortisone (cohort C: empiric dosing regimen)
Trial: 7666079
Drug: Suramin and
RxNorm normalized name: suramin
DrugBank: Suramin (DB04786)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suramin and hydrocortisone (sequential regimens)
Trial: 2572047
Drug: Salicylazosulfapyridine (SASP)
DrugBank: Sulfasalazine (DB00795)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Salicylazosulfapyridine (SASP) treatment
Trial: 31186389
Drug: Standard medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard medical care with no change in regular daily activities.
Trial: 29066877
Drug: Subcutaneous teriparatide
RxNorm normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subcutaneous teriparatide (20 μg/day)
Trial: 21676992
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg of lurasidone
Trial: 21676992
Drug: 120 mg
RxNorm normalized name: papain 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mg of lurasidone
Trial: 21676992
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg of olanzapine
Trial: 20112596
Drug: 15 mg/day
RxNorm normalized name: Climara Pro 0.045/0.015 MG/Day Weekly Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg/day elemental zinc
Trial: 9129883
Drug: Vasodilating beta-blockers
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vasodilating beta-blockers (e.g., carvedilol)
Trial: 9129883
Drug: Standard beta-blockers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard beta-blockers (e.g., metoprolol)
Trial: 8499737
Drug: HDivIg at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HDivIg at 500 mg/kg given over 2 h
Trial: 3677213
Drug: ASA (1300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASA (1300 mg) alone
Trial: 3677213
Drug: ASA (1300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASA (1300 mg) plus Ranitidine (150 mg)
Trial: 31879812
Drug: 60 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg/kg intravenous tranexamic acid (IV-TXA) before incision (Group B)
Trial: 31879812
Drug: 20 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/kg intravenous tranexamic acid (IV-TXA) before incision (Group A)
Trial: 31879812
Drug: 60 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg/kg intravenous tranexamic acid (IV-TXA)
Trial: 29936239
Drug: G-ICBT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-ICBT
Trial: 18557720
Drug: CP-690 550
RxNorm normalized name: CP
DrugBank: Captopril (DB01197)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CP-690 550 15 mg BID
Trial: 18557720
Drug: CP-690 550
RxNorm normalized name: CP
DrugBank: Captopril (DB01197)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CP-690 550 30 mg BID
Trial: 15303108
Drug: Lifestyle education
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lifestyle education group (LE‐G)
Trial: 15303108
Drug: Substitutional diet
RxNorm normalized name: hydroxypropyl cellulose, low substituted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Substitutional diet with guided physical activity (SD/PA‐G)
Trial: 15303108
Drug: Substitutional diet
RxNorm normalized name: hydroxypropyl cellulose, low substituted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Substitutional diet without guided physical activity (SD‐G)
Trial: 9266888
Drug: MDI albuterol
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDI albuterol (360 microg)
Trial: 9266888
Drug: NEB albuterol
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NEB albuterol (1.5 mg)
Trial: 9266888
Drug: MDI saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDI saline solution placebo
Trial: 9266888
Drug: NEB saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NEB saline solution placebo
Trial: 3521619
Drug: Dried garlic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dried garlic (3 X 198 mg) in Study I
Trial: 3521619
Drug: Dried garlic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dried garlic (3 X 450 mg) in Study II
Trial: 30683623
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of autogenous and xenogenous bone
Trial: 17646564
Drug: Echinacea purpurea
RxNorm normalized name: Echinacea purpurea
DrugBank: Echinacea purpurea (DB14239)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Echinacea purpurea (350 mg single dose)
Trial: 7694975
Drug: Cefmetazole 2
RxNorm normalized name: cefmetazole 20 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefmetazole 2 g by intravenous push immediately prior to incision
Trial: 7694975
Drug: Cefmetazole 2
RxNorm normalized name: cefmetazole 20 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefmetazole 2 g by intravenous push 15 to 60 minutes prior to incision
Trial: 1209435
Drug: High doses
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High doses of vitamins B6, B1 and B12
Trial: 28649870
Drug: Manual dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual dosing of 10 ml radiolabeled Wet® Original® lubricant
Trial: 28649870
Drug: Applicator dosing
RxNorm normalized name: Metered Dose Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Applicator dosing of 10 ml radiolabeled hydroxyethyl cellulose universal placebo gel
Trial: 28649870
Drug: Applicator dosing
RxNorm normalized name: Metered Dose Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Applicator dosing of 3.5 ml radiolabeled hydroxyethyl cellulose universal placebo gel
Trial: 24782286
Drug: 0.4 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg/kg pethidine
Trial: 24782286
Drug: 0.1 μg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 μg/kg sufentanil
Trial: 23148048
Drug: 300 g
RxNorm normalized name: Zantac 300 GELdose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 g of vegetables and 25 mL PUFA-rich plant oil per day
Trial: 12575566
Drug: Baisuifang Oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baisuifang Oral Liquid (BSF)
Trial: 7946935
Drug: Nimodipine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimodipine (30 mg three times daily)
Trial: 7946935
Drug: Diazepam (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (10 mg once daily)
Trial: 7946935
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (Nimodipine and Diazepam)
Trial: 3062266
Drug: biosynthetic human
RxNorm normalized name: Proinsulin biosynthetic human
DrugBank: Proinsulin human (DB17875)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: biosynthetic human NPH insulin (controls)
Trial: 25581701
Drug: Positive coping
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Positive coping strategies (e.g., problem solving, cognitive reframing)
Trial: 25581701
Drug: Negative coping
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Negative coping strategies (e.g., fighting, breaking things)
Trial: 20946583
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of bath PUVA and targeted UVB 308 nm excimer radiation
Trial: 9315401
Drug: Expectant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Expectant therapy with metoclopramide
Trial: 9315401
Drug: Antiemetic use
RxNorm normalized name: ANTIEMETICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiemetic use in expectant therapy groups
Trial: 2872720
Drug: High-dose fluoxymesterone
RxNorm normalized name: Fluoxymesterone
DrugBank: Fluoxymesterone (DB01185)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-dose fluoxymesterone (1 mg/kg/d)
Trial: 2872720
Drug: High-dose norethandrolone
RxNorm normalized name: norethandrolone
DrugBank: Norethandrolone (DB12787)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose norethandrolone (1 mg/kg/d)
Trial: 2872720
Drug: Low-dose fluoxymesterone
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose fluoxymesterone (0.2 mg/kg/d)
Trial: 2872720
Drug: Low-dose norethandrolone
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose norethandrolone (0.2 mg/kg/d)
Trial: 2872720
Drug: High doses
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High doses of 4 different androgens
Trial: 2872720
Drug: Fluoxymesterone (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxymesterone (1 mg/kg/d) for 18 months
Trial: 29193980
Drug: Estradiol vaginal
RxNorm normalized name: Estradiol Vaginal
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Estradiol vaginal cream 0.003% (15 μg estradiol; 0.5 g cream), applied vaginally once daily for 2 weeks followed by two applications/week for 10 weeks.
Trial: 29193980
Drug: Estradiol vaginal
RxNorm normalized name: Estradiol Vaginal
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Estradiol vaginal cream 0.003%
Trial: 29193980
Drug: Placebo (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0.5 g cream), applied vaginally once daily for 2 weeks followed by two applications/week for 10 weeks.
Trial: 25028375
Drug: Etanercept (ETN)
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Etanercept (ETN) treatment for 3 years
Trial: 15882537
Drug: Telmisartan 80
RxNorm normalized name: telmisartan 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telmisartan 80 mg/HCTZ 12.5 mg daily
Trial: 15882537
Drug: Nifedipine GITS
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine GITS 60 mg daily
Trial: 12795769
Drug: Alefacept (0.025
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alefacept (0.025 mg/kg, 0.075 mg/kg, or 0.150 mg/kg)
Trial: 27899759
Drug: Intensive antihypertensive
RxNorm normalized name: ANTIHYPERTENSIVES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive antihypertensive treatment aiming for systolic BP 120-140 mmHg
Trial: 27899759
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment aiming for systolic BP 140-180 mmHg
Trial: 24635483
Drug: Photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photodynamic therapy (PDT) for solar keratosis (SK) grade I-II.
Trial: 23809328
Drug: 0.8g of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.8g of c9,t11CLA daily for two months
Trial: 23809328
Drug: 1.6g of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.6g of c9,t11CLA daily for two months
Trial: 23809328
Drug: 3.2g of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.2g of c9,t11CLA daily for two months
Trial: 10827393
Drug: Streptokinase treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Streptokinase treatment initiated within the first 1.5 hours (group A)
Trial: 10827393
Drug: Very early
RxNorm normalized name: Primula veris extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Very early fibrinolytic therapy
Trial: 17888558
Drug: 500‐mg GTPs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500‐mg GTPs
Trial: 17888558
Drug: 1000‐mg GTPs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000‐mg GTPs
Trial: 15950853
Drug: Epidural anesthesia
RxNorm normalized name: Epidural Anesthesia Tray
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epidural anesthesia with 1.0% ropivacaine with 1:200,000 epinephrine and analgesia with 0.2% ropivacaine at 8 mL/h, maintained for 7 days
Trial: 15950853
Drug: Spinal anesthesia
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal anesthesia with 0.5% bupivacaine and analgesia with intravenous patient‐controlled analgesia morphine, demand mode only
Trial: 10569604
Drug: 0.4 mg
RxNorm normalized name: biotin 0.4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg desmopressin
Trial: 10569604
Drug: 0.8 mg
RxNorm normalized name: biotin 0.8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.8 mg desmopressin
Trial: 10569604
Drug: Anticholinergic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticholinergic treatment
Trial: 8935931
Drug: Diazepam (0.03
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (0.03 mL/Kg of 5 mg/mL solution)
Trial: 1714886
Drug: Amsacrine (AMSA)
RxNorm normalized name: amsacrine
DrugBank: Amsacrine (DB00276)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amsacrine (AMSA) at 100 mg/M2 daily for 5 days and etoposide at 200 mg/M2 daily for the first 3 days of therapy
Trial: 1714886
Drug: Amsacrine (AMSA)
RxNorm normalized name: amsacrine
DrugBank: Amsacrine (DB00276)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amsacrine (AMSA) and etoposide plus azacitidine (AZ) at a dosage of 250 mg/M2 on days 4 and 5
Trial: 25201459
Drug: tamsulosin 0.4
RxNorm normalized name: tamsulosin 0.4 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tamsulosin 0.4 mg for 4 weeks
Trial: 27811309
Drug: Triple antiplatelet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple antiplatelet therapy (combined aspirin, clopidogrel, and dipyridamole)
Trial: 27811309
Drug: Guideline treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guideline treatment (control group)
Trial: 15752381
Drug: Ebastine +
RxNorm normalized name: ebastine
DrugBank: Ebastine (DB11742)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ebastine + Ketoconazole (20 mg qd + 450 mg qd)
Trial: 15752381
Drug: Loratadine +
RxNorm normalized name: Loratadine
DrugBank: Loratadine (DB00455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Loratadine + Ketoconazole (10 mg qd + 400 mg qd)
Trial: 15752381
Drug: Ketoconazole +
RxNorm normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketoconazole + Placebo (450 mg qd or 400 mg qd)
Trial: 15752381
Drug: Ebastine +
RxNorm normalized name: ebastine
DrugBank: Ebastine (DB11742)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ebastine + Placebo (20 mg qd)
Trial: 15752381
Drug: Loratadine +
RxNorm normalized name: Loratadine
DrugBank: Loratadine (DB00455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Loratadine + Placebo (10 mg qd)
Trial: 12110818
Drug: HFA‐BDP Autohaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HFA‐BDP Autohaler at half the daily dose (100-200 microg)
Trial: 7428401
Drug: Cefuroxime 750
RxNorm normalized name: cefuroxime 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefuroxime 750 mg, 1 dose
Trial: 7428401
Drug: Cefuroxime 750
RxNorm normalized name: cefuroxime 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefuroxime 750 mg, 7 doses
Trial: 7428401
Drug: Cefuroxime 1.5
RxNorm normalized name: cefuroxime 1.5 GM Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefuroxime 1.5 g, 1 dose
Trial: 7428401
Drug: Cefuroxime 1.5
RxNorm normalized name: cefuroxime 1.5 GM Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefuroxime 1.5 g, 7 doses
Trial: 17125424
Drug: Lactobacillus intravaginal
RxNorm normalized name: Lactobacillus reuteri
DrugBank: Lactobacillus reuteri (DB14224)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus intravaginal capsule
Trial: 17125424
Drug: Placebo intravaginal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo intravaginal capsule
Trial: 14702508
Drug: Overall prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall prescription rates (all groups)
Trial: 2039190
Drug: Schedule 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Schedule 2 (30 mg/kg over 2 days; one dose of 10 mg/kg followed by two doses of 5 mg/kg at 6‐h intervals on the first day and two doses of 5 mg/kg at 12‐h intervals on the second day)
Trial: 2039190
Drug: Schedule 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Schedule 1 (25 mg/kg over 3 days)
Trial: 31793465
Drug: Control (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (200 mL of tap water)
Trial: 24606094
Drug: ω-3 FAEE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ω-3 FAEE supplementation (4 g/d)
Trial: 22500390
Drug: Zaizao Shengxue
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zaizao Shengxue Tablet (ZST)
Trial: 17559735
Drug: Darbepoetin alfa
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Darbepoetin alfa correction/maintenance dosing (4.5 microg/kg weekly for 4 weeks followed by 4.5 microg/kg every 3 weeks)
Trial: 17559735
Drug: Darbepoetin alfa
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Darbepoetin alfa weekly dosing (2.25 microg/kg weekly)
Trial: 17559735
Drug: Darbepoetin alfa
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Darbepoetin alfa correction/maintenance dosing
Trial: 17559735
Drug: Darbepoetin alfa
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Darbepoetin alfa weekly dosing
Trial: 10408592
Drug: Eprosartan (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eprosartan (200 or 300 mg b.i.d.)
Trial: 10408592
Drug: Enalapril (5‐20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (5‐20 mg u.i.d.)
Trial: 7677298
Drug: Dapsone 100
RxNorm normalized name: dapsone 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapsone 100 mg administered alone
Trial: 7677298
Drug: Dapsone 100
RxNorm normalized name: dapsone 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapsone 100 mg administered with didanosine placebo tablets (group 1)
Trial: 7677298
Drug: Dapsone 100
RxNorm normalized name: dapsone 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapsone 100 mg administered with active didanosine tablets (group 2)
Trial: 6754492
Drug: 50 g
RxNorm normalized name: glucose 50 g/296 mL oral liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 g oral glucose tolerance test
Trial: 31905410
Drug: Amniotic suspension
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amniotic suspension allograft injection
Trial: 17498420
Drug: 0.25 percent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 percent tetracycline aqueous solution mouthwash
Trial: 18005429
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg of folic acid
Trial: 15160440
Drug: Rupatadine 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rupatadine 20 mg (R20)
Trial: 15160440
Drug: Rupatadine 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rupatadine 10 mg (R10)
Trial: 1385586
Drug: Clodronate (3.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clodronate (3.2 g for the first month, thereafter 1.6 g)
Trial: 1385586
Drug: Clodronate (3.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clodronate (3.2 g and 1.6 g)
Trial: 1385586
Drug: Clodronate (3.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clodronate (3.2 g)
Trial: 6719513
Drug: Computerized tomography
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computerized tomography for localization of treatment volume